SmartCella is a global biotechnology company combining novel delivery platforms with cell and mRNA therapies. Its core product is the FDA-cleared Extroducer, an endovascular device that enables direct infusion to hard-to-reach organs and tumors. The company operates two business segments: Targeted Delivery and Cell/mRNA Therapies. Proceeds from the recent capital raise will be used to accelerate growth, support commercialization of the Extroducer, and expand the company’s cell and mRNA operations. Management plans continued investment in organization, infrastructure, commercialization, and marketing to drive adoption. The team is composed of scientists and industry veterans focused on building clinical evidence to advance targeted medicines.

Total raised

$54M

Funding rounds

1

Latest round

Equity

Latest activity

Jul 2024